Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2: Induction of autologous tumour-reactive CD4+ Th1 killer lymphocytes by Yamaguchi, Y et al.
Locoregional immunotherapy of malignant effusion from
colorectal cancer using the streptococcal preparation OK-432 plus
Interleukin-2
Induction of autologous tumour-reactive CD4þ Th1 killer lymphocytes
Y Yamaguchi*,1, E Miyahara
1, A Ohshita
1, Y Kawabuchi
1, K Ohta
1, K Shimizu
1, K Minami
1, J Hihara
1,
A Sawamura
1 and T Toge
1
1Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
In total, 16 patients with cytologically proven malignant effusion from colorectal cancer were treated by locoregional administration of
the streptococcal preparation OK-432 alone or OK-432 plus the T-cell growth factor interleukin (IL)-2, and the action mechanism of
the treatment was studied. A positive clinical response, showing a cytologic disappearance of cancer cells and decrease of effusion,
was observed in nine of 11 (82%) patients treated with OK-432 alone and in all five patients treated with OK-432 plus IL-2. Flow
cytometric analysis revealed that OK-432 plus IL-2 locally induced acute inflammation-like responses, including serial cellular
infiltrations of granulocyte migration within a matter of hours, and activation of macrophages and T lymphocyte involvement within
the following days, and that a predominant expansion of CD3þCD4þ lymphocytes (CD: cluster of differentiation) was induced by
in vitro stimulation with IL-2 of locoregional cells after the OK-432 administration (OK/IL-2AK cells). The OK/IL-2AK cells produced
tumour necrosis factor-a and interferon-g, but these cells did not produce IL-4 and IL-6. The OK/IL-2AK cells expressed potent killing
activity against autologous tumour cells. This activity was abrogated by treatment of the lymphocytes with anti-CD3, -CD4, -TCRab
antibody, and by the treatment of target cells with anti-human leukocyte antigen (HLA)-DR antibody. The OK/IL-2AK cells expressed
Fas-L gene, and flow cytometric analysis demonstrated HLA-DR expression in approximately 75% of CEAþ or cytokeratinþ
effusion cells. TCRVb gene analysis of the OK/IL-2AK cells showed an oligoclonal usage of TCRb20, which was also involved in the
cytotoxic mechanism of the OK/IL-2AK cells. Single-strand conformational polymorphism analysis demonstrated the clonotypes for
the TCRVb20 gene, and the CDR3s of the gene were sequenced. The clonotypic PCR using the TCRVb20-CDR3 sequences could
detect the CDR3-identical TCRs in effusion lymphocytes from the other patients. Taken together, it is suggested that locoregional
administration of OK-432 plus IL-2 is highly effective for the management of malignant effusion from colorectal cancer. OK-432 plus
IL-2 induces autologous tumour-reactive CD4þ Th1 killer lymphocytes, which recognise tumour antigen(s) presented with HLA
class II molecules on effusion tumour cells by means of preferential usage of TCRVb20. The clonotypic PCR using the TCRVb20-
CDR3 sequences may be informative for treating malignant effusion from colorectal cancer using OK-432 plus IL-2.
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Malignant effusion is often a complication in primary or refractory
cancer patients. Malignant effusion is a poor prognostic factor;
20% of patients die within 1 month, and the median survival is
only a few months (Miles and Knight, 1993). When the effusion is
diagnosed, 75% of patients have several objective and subjective
symptoms such as anorexia, a full abdominal sensation, cough,
and dyspnoea, which are sometimes difficult to be managed.
Locoregional administration of various agents, including anti-
neoplastic chemotherapeutic drugs (Kimura et al, 1998), biological
response modifiers for immunotherapy (Driesen et al, 1994), and
gene therapy agents (Hsiao et al, 1997) by paracentesis may be
effective for the treatment of malignant effusion due to the
pharmacokinetic advantages of drug delivery.
OK-432 is one of the most popular anticancer drugs and is the
only agent approved for locoregional use in patients with
malignant effusion in Japan (Nio et al, 1999; Gochi et al, 2001).
It is a penicillin- and heat-inactivated lyophilised powder of
Streptococcus pyogenes A3. OK-432 modifies host cellular immune
responses biologically to potentiate antitumour activities. The
mechanisms responsible for the antitumour activity of OK-432
have previously been characterised. Uchida and Micksche (1983)
demonstrated that intrapleural administration of OK-432 augmen-
ted the effusion of natural killer (NK) cell activity and reduced the
effusion of NK suppressor cell activity. Katano and Torisu (1983)
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administration of OK-432. Moreover, OK-432 has been reported to
activate tumoricidal macrophages (Uchida and Klein, 1985) and to
involve T cells (Ozaki et al, 1990).
We have investigated locoregional immunotherapy for malig-
nant effusion, and have previously reported the clinical efficacy of
the combined administration of OK-432 plus the T-cell growth
factor interleukin-2 (IL-2) in gastric cancer patients. In that report,
we suggested that the efficacy of locoregional immunotherapy for
malignant effusion using OK-432 plus IL-2 was dependent on an
induction of CD4þ effector lymphocytes (CD: cluster of
differentiation) (Yamaguchi et al, 1995). In the present study, we
demonstrated a high efficacy of the locoregional immunotherapy
using OK-432 alone or OK-432 plus IL-2 for malignant effusion
from colorectal cancer. Furthermore, locoregional cells were
analysed in order to clarify the mechanisms involved in the
locoregional immunotherapy using OK-432 plus IL-2.
MATERIALS AND METHODS
Locoregional immunotherapy for malignant effusion using
OK-432 plus IL-2
Since 1996, 16 colorectal cancer patients with cytologically proven
malignant effusion were experienced and treated with OK-432
alone or with OK-432 plus IL-2 in our department, after patients
gave informed consent (Yamaguchi et al, 1995). Briefly, 0.2–5KE
of OK-432, which was dissolved in 10ml of saline, was
locoregionally administered at the time of paracentesis after the
removal of the effusion, and was followed by administration of
100000IU of IL-2 (TGP-3, Takeda Pharmaceutical Co., Ltd.,
Osaka) in saline 3–7 days later. The clinical efficacy of the
treatment was assessed by cytological, X-ray and computed
tomographic examinations before and 1 month after the treatment,
and a positive response was defined when effusion had either
disappeared or decreased, with negative cytology results persisting
for more than 1 month. Sonographic examinations were made
weekly to address the assessment of clinical responses. All patients
had already received concurrent chemotherapy of 5-fluorouracil
(600mgm
 2, weekly) plus leucovorin (250mgm
 2, weekly), which
had failed to inhibit the effusion.
Collection of effusion lymphocytes and tumour cells
Citrated effusion was obtained before OK-432 administration.
A portion of the effusion was subjected to a whole effusion
assay, described below. Another portion of the effusion was
processed in order to collect effusion cells. Cells were pelleted
and resuspended in RPMI-1640 medium and layered on a
75%/100% Ficoll–Conray gradient. After centrifugation at
800g for 25min, autologous tumour cells were collected from
the 75% interface and mononuclear cells were collected from the
100% interface. Tumour cells were washed three times with RPMI-
1640 medium and were frozen in fetal bovine serum supplemented
with 10% DMSO until they were used as a target for the
cytotoxicity assays. After OK-432 administration, the effusion
mononuclear cells were collected again, washed, and further
incubated in RPMI-1640 medium supplemented with 2% heat-
inactivated autologous serum and 100Uml
 1 IL-2 for 7–21 days.
The OK-432 and IL-2-activated killer (OK/IL-2AK) cells were
harvested and subjected to further experiments. Human leukocyte
antigen (HLA) haplotypes of the patients were serologically
measured at SRL Inc., Tokyo.
Flow cytometry (FCM) and monoclonal antibodies
Effusion cells (50ml) before and after the treatment and OK/IL-
2AK cells (5 10
5) were incubated with fluorescein isothiocyanate
(FITC) or phycoerythrin (PE)-labelled monoclonal antibodies at
41C for 45min. The monoclonal antibodies used were anti-Leu4a
(CD3), -Leu3a (CD4), -Leu2a (CD8), -Leu19 (CD56), -Leu15
(CD11b), -HLA-DR, - T-cell receptor (TCR)ab (Becton Dickinson,
San Jose, CA, USA), -TCRVb20, -HLA-ABC, (Immunotech,
Marseille, France), -carcinoembryonic antigen (CEA) (DAKO, A/
S, Denmark), -cytokeratin AE1/AE3 (DAKO Co., CA, USA)
antibodies. To determine the HLA-DR expression in tumour cells,
effusion cells (5 10
5) were incubated with anti-CEA or -
cytokeratin antibody followed by PE-labelled rat anti-mouse Igk
light-chain antibody (BD Biosciences, Tokyo); cells were then
washed three times and stained with FITC-labelled anti-HLA-DR
antibody. Finally, the cells were washed twice and resuspended in
phosphate-buffered saline. Flow cytometric analysis was per-
formed using a Cytoron (Ortho Diagnostic Systems, USA). After
the cells were adequately gated by using a forward and side scatter,
data collection was set up to stop when 10000 events had been
analysed.
Cytotoxicity assay
The cytotoxic activity of the lymphocytes was determined using a
standard
51Cr releasing assay. In brief,
51Cr-labelled autologous
tumour cells (5 10
3) and various numbers of effector lympho-
cytes were cocultured in 96-well round-bottomed microtitre plates
at a volume of 200ml. After 4h of incubation at 371C, the
radioactivity of the supernatants was measured using an auto-
gamma scintillation counter (500C, Packard, USA). Spontaneous
release was determined in wells containing the target cells alone,
and maximum release was obtained by adding 100ml of 1% Triton
X-100 solution instead of the effector cells over the target cells.
Cytotoxic activity was calculated from triplicate samples using the
following formula: cytotoxic activity (%)¼(experimental release
(cpm) spontaneous release (cpm))/(maximal release
(cpm) spontaneous release (cpm)) 100. To explore the lympho-
cyte phenotype and molecules involved in the cytotoxic mechan-
ism, either effector cells or target cells were treated with the
corresponding antibodies at 41C for 1h, washed, and then
subjected to cytotoxicity assay.
Cytokine assay
A simple whole effusion assay, which imitated in vivo treatment,
was performed to predict the responsiveness of effusion to OK-432
treatment before the onset of treatment. In brief, aliquots of
effusion (0.5ml) were directly diluted with RPMI-1640 medium
(4.5ml) and stimulated with 0.1KEml
 1 of OK-432. After
24h under standard culture conditions, the supernatants were
collected and tumour necrosis factor (TNF)-a production was
measured using an ELISA kit (R & D Systems, Minneapolis,
MN, USA).
A profile of cytokine production by OK/IL-2AK cells was also
measured by enzyme-linked immunosorbent assay (ELISA).
Aliquots of OK/IL-2AK cells were collected, washed, and
resuspended in RPMI-1640 medium containing IL-2 at a cell
density of 10
6ml
 1. After being incubated for another 48h, the
culture supernatants were collected by centrifugation, and the
production of interferon (IFN)-g, TNF-a, IL-4, and IL-6 was
measured using an ELISA kit specific for each cytokine (R & D
Systems, Minneapolis, MN, USA).
Reverse transcription–polymerase chain reaction
(RT–PCR) analysis for Fas-L expression
RT–PCR was performed in order to analyse the Fas-L gene. In
brief, total cellular RNA was extracted by acid guanidinium
thiocyanate–phenol–chloroform extraction, and RNA samples
were reverse-transcribed into cDNA with a random hexamer
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performed in a reaction mixture consisting of cDNA samples, Taq
polymerase (Gibco BRL, USA) and the following primers: Fas-L, 50-
ATAGGATCCATGTTTCTGCTCTTCCACCTACAGAAGGA-30, and
50-ATAGAATTCTGACCAAGAGAGAGCTCAGATACGTTGAC-30
(Yasukawa et al, 1999); b-actin (Stratagene, La Jolla, CA, USA). The
reaction was carried out on a Perkin-Elmer Cetus thermal cycler,
under conditions involving a 3-min denaturation at 941C followed
by 35 cycles of 1min at 941C, 1min at 551C, and 1min at 721C.
After amplification, 8ml of the reaction mixture was removed and
analysed by means of electrophoresis through 2.0% agarose gels in
Tris-borate-EDTA buffer, and the gels were then stained with
ethidium bromide. The expected lengths of the amplified cDNAs
were 506 and 514bp for Fas-L and b-actin, respectively.
TCRVb gene analysis by RT–PCR–Southern blotting
TCRVb gene analysis by RT–PCR was performed as above
mentioned using primers specific for TCRVb genes, which have
been previously described in detail (Miyahara et al, 1996). The
amplified DNA was confirmed by Southern blot analysis using the
Cb sequence with luminous reaction. Briefly, 8ml of each amplified
product was run on a 1% agarose gel and transferred onto a nylon
membrane (Hybond-Nþ, Amersham International plc, Aylesburg,
UK). The membranes were hybridised at 421C for 4h with
10ngml
 1 of probe specific for Cb forward, which had been
labelled at its 30 end with fluorescein-d UTP (ECL 30-oligolabelling
and detection systems, Amersham International plc, Aylesburg,
UK). After incubation with the antifluorescein HRP, hybridised
probes were detected by the light (lmax, 428nm) emitted from the
oxidation of luminol-coupled peroxidase. The light output was
detected on X-ray film.
Diagnostic SSCP analysis
To detect single-base mutations in the PCR products of the TCRVb
gene, the single-strand conformation polymorphism (SSCP)
technique was used (Orita et al, 1989). In brief, 5ml of the
asymmetric PCR product, which was mixed with 5ml of 95%
formamide containing xylen cyanol and bromophenol blue, was
heated at 951C for 5min, cooled on ice, and loaded onto a 10%
acrylamide mini-gel (Mino-Protean II, Bio-Rad, Hercules, CA,
USA). This gel was run at 100V for 4h in a cold room (41C). The
gel was then silver stained (Silver Stain Plus, BioRad, Hercules, CA,
USA).
Sequencing of TCR Vb gene and clonotypic PCR
After SSCP analysis, the amplified DNA was eluted from the
acrylamide gel and either directly sequenced in the Gene Analysis
Center (Takara Shuzo Co., Ltd, Ohtsu) or cloned in the pCRTM
vector, according to the TA cloning kit procedure (Invitrogen, San
Diego, CA, USA), and the DNA was subsequently used to
transform Esherichia coli-competent cells. Plasmid DNA of
recombinant colonies was prepared (Wizard, QIAGEN Inc.,
Chatsworth, CA, USA) and sequenced using the DyeDeoxy
Terminator Cycle sequencing kit and 373 DNA Sequencer (Applied
Biosystems Inc, Foster City, CA). Definition of complementarity-
determining region (CDR) 3-like boundaries was accomplished
using methods described by Toyonaga et al (1985). CDR3
oligonucleotides were chosen with the help of the Oligo 4.0
computer program and were synthesised by Biologica Inc
(Nagoya). Clonotypic PCR was performed using each oligonucleo-
tide as the forward primer and Cb reverse primer, followed by
Southern blot hybridisation with the probe specific for the Cb
forward sequence.
Statistical analysis
Statistical evaluation of the experimental values was performed
using paired and unpaired Student’s t-test.
RESULTS
Characteristics of patients enrolled in locoregional
immunotherapy of malignant effusion using OK-432
The characteristics of the 16 patients included in the present study
are listed in Table 1. The patients had a median age of 59 ranging
from 39 to 72 years old, included seven males and nine females,
and showed PS values of 0–3. Primary lesions were located at
ascending, transverse, sigmoid colons, and rectums. A total of 14
patients had undergone prior resection of the primary tumour. In
total, 14 patients had well to moderately differentiated adenocar-
cinomas and two patients did mocinous ones in histology of the
primary lesions. In all, 13 patients had ascites and three did pleural
effusion, and all patients had concurrent liver, lung, lymph node,
and bone metastases as well as effusions detectable by CT scan.
Clinical response of locoregional treatment for malignant
effusion using OK-432
The clinical efficacy of locoregional immunotherapy using OK-432
or OK-432 plus IL-2 is shown in Table 2. Initially, 11 patients were
treated with OK-432 alone and another five patients were done
with OK-432 plus IL-2. The response rate of locoregional
immunotherapy for malignant effusion was 82% with OK-432
alone and 100% with OK-432 plus IL-2, showing the overall
response rate of 88%. Subsequently, symptoms due to malignant
effusion appeared to improve in responder patients (data not
shown). No patients except two had a clinical relapse of effusion
after the immunotherapy using OK-432 or OK-432 plus IL-2. The
survival of each treatment group was similar, and the overall
median survival was 8 months ranging from 1 to 21 months. As
adverse effects, all patients had fever elevation of 37–381C and
four patients (25%) had abdominal or thoracic pain, both of which
could be well-managed with an occasional administration of
nonsteroidal anti-inflammatory drugs (data not shown).
Table 1 Characteristics of colorectal cancer patients enrolled in the trial
of locoregional immunotherapy for malignant effusion
Age: median (range) 59 (39–72)
Gender (male/female) 7/9
Performance status (0/1/2/3) 1/3/9/3
Primary site (A/T/S/R)
a 3/2/7/4
Primary operation (yes/no) 14/2
Histology
Differentiated type
b 14
Undifferentiated type
c 2
Effusion
Pleural 3
Ascites 13
Concurrent metastasis
Liver 10
Lung 3
Lymph nodes 12
Bone 2
aA¼ascending; T¼transverse; S¼sigmoid; R¼rectum.
bDifferentiated type
included well to moderately differentiated adenocarcinomas.
cMucinous adenocarci-
noma.
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OK-432 plus IL-2 treatment
Effusion cells were collected before and after OK-432 plus IL-2
administration, and cytogram analysis was performed using FCM
to determine the changes in the infiltrated cell population.
Representative cytograms obtained from two patients with
malignant effusion are shown in Figure 1. Granulocytes, the
population of which was found to have high side scatter and
intermediate forward scatter, migrated into the cavity in great
numbers even 4h after the administration of OK-432. This
population peaked on day 1, and then decreased. This granulocyte
mobilisation was closely correlated clinically with the febrile
condition of the patients after the OK-432 administration.
Macrophages, which had intermediate side scatter and large
forward scatter, followed the granulocyte accumulation into the
cavity. Lymphocytes, which had low side scatter and small forward
scatter, accumulated gradually after the OK-432 administration
and were remarkably concentrated by IL-2 administration in vivo.
Phenotype analysis and cytokine production of
OK/IL-2AK cells
Effusion cells after OK-432 administration were collected and
further stimulated in vitro with IL-2 (OK/IL-2AK cells) and
characterised by FCM. The representative profile is shown in
Figure 2. The OK/IL-2AK cells were 95% CD3þCD4þ, but were
only 8% CD8þ and 11% CD56þ on day 14 of the culture. Similar
phenotypic changes were obtained in the OK/IL-2AK cells from the
three patients who were examined. Culture supernatants of the
OK/IL-2AK cells were also collected, and cytokine production was
examined using ELISA (Table 3). The OK/IL-2AK cells (10
6ml
 1)
produced high levels of IFN-g (954–2000Uml
 1) and TNF-a
(883–3810pgml
 1), but only marginal levels of IL-4 and IL-6 were
produced during 48h in the presence of IL-2. Effusion cells before
OK-432 administration showed a diverse pattern of cytokine
production; IFN-g and TNF-a were marginally detectable, and IL-6,
on the other hand, was sometimes high at a concentration (data
not shown).
Cytotoxic property of OK/IL-2AK cells
A cytotoxicity assay was performed to explore the cytotoxic
properties of this predominant CD4þ population (Table 4). The
Table 2 Clinical responses of locoregional immunotherapy using OK-
432 alone or OK-432 plus IL-2 for malignant effusion from colorectal
cancer
Immunotherapy
Efficacy OK-432 OK-432+IL-2 Total
Response (%) 9/11 (82) 5/5 (100) 14/16 (88)
Disappeared 7 (64) 4 (80) 11 (69)
Decreased 2 (18) 1 (20) 3 (19)
Duration (months)
Median 6 8 8
Range 1–16 3–16 1–16
Suvival (months)
Median 6 8 8
Range 1–21 3–19 1–21
Case 1
Case 2
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Figure 1 Serial cellular infiltration after administration of OK-432 plus IL-2. OK-432 and IL-2 were administered into malignant effusion and locoregional
cells were analysed by FCM on the days indicated. Representative cytograms obtained from two patients with malignant effusion were shown.
Autologous tumour-reactive CD4þTh1 killer cells
Y Yamaguchi et al
1879
British Journal of Cancer (2003) 89(10), 1876–1884 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lOK/IL-2AK cells, obtained from a rectal cancer patient with an
excellent effusion response, showed potent cytotoxic activity (84%)
against autologous tumour cells at an effector-to-target (E/T) ratio
of 100. This activity appeared to be higher than that observed
before the treatment (pre-OK). The cytotoxicity of the OK/IL-2AK
cells was almost completely abrogated by the treatment of effector
cells with either anti-CD3 (32%) or -CD4 (37%) antibody prior to
the cytotoxicity assay. The cytotoxicity was not affected at all by
anti-CD8 antibody, and was only slightly affected by anti-CD56
antibody (72%). The cytotoxicity was also reduced when the OK/
IL-2AK cells were treated with anti-TCRab antibody (41%), and
when tumour cells were treated with anti-HLA-DR antibody (36%).
However, treatment of the effector cells with irrelevant Ig had no
effect on the cytotoxicity generated. When an irrelevant target cell
line, K562, was used in the cytotoxicity assay, no remarkable
augmentation of the cytotoxicity of the OK/IL-2AK cells was
observed, nor was there an inhibitory effect with the use of anti-
TCRab antibody.
Fas-L expression in OK/IL-2AK cells
Fas-L expression was examined using RT–PCR for the OK/IL-2AK
cells. Representative data are shown in Figure 3. We were unable to
detect positive bands of Fas-L expression in the effusion cells
before OK-432 administration. However, the OK/IL-2AK cells
showed positive bands for Fas-L expression in patients analysed.
HLA-DR expression in effusion tumour cells
The HLA-DR expression in effusion tumour cells was examined by
FCM (Table 5). HLA-DR expression was detectable in 8–87% of
the effusion cells, as determined by single colour analysis. CEAþ
cells and cytokeratinþ cells were detected in 7–75 and 19–66% of
the effusion cells, respectively. Two-colour analysis showed that
5–68% of the effusion cells were of the HLA-DRþCEAþ
phenotype and 6–63% of the cells were of the HLA-
DRþcytokeratinþ phenotype, indicating that approximately
75% of the CEAþ cells or cytokeratinþ cells expressed HLA-
DR molecules on their cell surface.
TCRVb gene usage analysis of OK/IL-2AK cells
We next analysed the TCRVb gene usage of the OK/IL-2AK cells
from the rectal cancer patient (Figure 4). The TCRVb gene analysis
demonstrated a diverse expression of TCR genes in the effusion
cells before OK-432 administration (pre-OK cells). In contrast, an
oligoclonal expression of TCRVb13.2 and TCRVb20 genes was
observed in the OK/IL-2AK cells of this patient. Flow cytometric
analysis showed that TCRVb20þ lymphocytes accounted for 15%
of the pre-OK cells and 26% of the OK/IL-2AK cells (data not
shown). The cytotoxicity of the OK/IL-2AK cells was significantly
reduced when the OK/IL-2AK cells were treated with anti-TCRVb20
antibody (49%) (Po0.01) (Table 3).
CDR3 sequences of the TCRVb20 gene
To identify the CDR3 sequences, the PCR products of TCRVb
genes from the same patient were examined by SSCP analysis of
the TCRVb13.2 gene of the OK/IL-2AK cells; this SSCP analysis
failed to detect clonotypic bands and demonstrated a smear
pattern (data not shown). On the other hand, three pairs of
clonotypic bands were detectable in the TCRVb20 gene of the OK/
IL-2AK cells (Figure 5). The sequencing analysis demonstrated
three CDR3 boundaries, which had diverse regions of Db2, Db1,
and Db2 and joining regions of Jb2.1, Jb1.5, and Jb2.1, respectively.
There was no similarity among the CDR3 sequences at the
nucleotide level, nor at the amino-acid level.
Clonotypic PCR amplification for detecting CDR3-identical
TCRs
According to the sequences of the CDR3 boundaries, we designed
forward primers (shown in Figure 5), which were designated as
Vb20-1, -2, and -3, to perform the clonotypic PCR analysis for
detecting the TCRs, the CDR3 sequences of which were identical to
those cloned from the TCRVb20 gene. The expected sizes of the
clonotypic PCR products were 245, 251, and 257bp for Vb20-1, -2,
and -3, respectively (Figure 5). The clonotypic PCR was performed
for pre-OK cells and OK/IL-2AK cells in seven patients. Lane 1
indicated the patient from whom the primer sequences of Vb20-1,
-2, and -3 were cloned. Positive bands were detectable at expected
sizes in all PCRs of lane 1 from pre-OK cells, and were augmented
in those from OK/IL-2AK cells (Figure 6). Positive bands were also
detectable in lanes 2–7 to various extent, indicating that the
CDR3-identical TCR-bearing T lymphocytes existed in OK/IL-2AK
cells of the other patients.
DISCUSSION
It was observed that malignant effusion from colorectal cancer
decreased or disappeared successfully in more than 80% patients
when treated with a simple, easily administered streptococcal
preparation OK-432 alone or in combination with T-cell growth
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Figure 2 Phenotype analysis of OK/IL-2AK cells. Effusion lymphocytes were collected after OK-432 administration and stimulated in vitro with IL-2 for 7–
21 days. Cells were subjected to phenotype analysis using Cytoron.
Table 3 Cytokine production profiles of OK/IL-2AK cells
Cytokines Case 1 Case 2 Case 3
IFN-g (Uml
 1) 2000 1044 954
TNF-a (pgml
 1) 3810 2710 883
IL-4 (pgml
 1)8 1 2 o4
IL-6 (pgml
 1) 3 20 11
Effusion cells were collected after OK-432 administration and stimulated in vitro with
IL-2. OK/IL-2AK cells (10
6ml
 1) were cultured for 48h and cytokine production in
supernatant was evaluated using ELISA.
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patients, in which the earlier study reported that positive clinical
responses were obtained in 60 and 81% when treated with OK-432
alone and with OK-423 plus IL-2, respectively (Yamaguchi et al,
1995). This difference may be explained, in part, by the histological
types, in which colorectal cancer patients had mainly well to
moderately differentiated adenocarcinomas, whereas gastric can-
cer patients did poorly differentiated adenocarcinomas. Although
malignant effusions from colorectal cancer were successfully
treated with our immunotherapy, its effects on the distant
metastases were marginal and all patients died. Nevertheless,
symptoms of patients with malignant effusion was subsequently
improved by our simple treatment, indicating that our immu-
notherapy was important for quality of life of the patients even if
they had poor prognoses (Miles and Knight, 1993).
We wanted to understand the mechanism of action of this
effective immunotherapy for malignant effusion from colorectal
cancer. It was observed using FCM that OK-432 induced locally
acute inflammation-like responses, including serial cellular infil-
trations of the granulocyte migration in a matter of hours and
activation of macrophages with T lymphocyte involvement in the
following days. This observation was similar to those included in
previous descriptions. Katano and Torisu (1982) reported that all
adenocarcinoma cells in malignant ascites disappeared within at
least 36h after OK-432 injection, while the number of intraper-
itoneal neutrophils increased. These neutrophils had a cytostatic
effect on ascites-derived tumour cells in vitro (1982). This OK-432-
induced neutrophil infiltration and activation may be understood
by the property of OK-432 to act as a bacterial preparation.
Table 4 Cytotoxic property of OK/IL-2AK cells
Treatment Autologous tumour cell target K562 cell target
Effector cells Target cells Pre-OK OK/IL-2AK Pre-OK OK/IL-2AK
—— 4 2 712 84735 2 746 2 71
Control Ig — 47788 3 712 51756 0 72
Anti-CD3 — — 32715** — —
Anti-CD4 — — 37711** — —
Anti-CD8 — — 8977— —
Anti-CD56 — — 7277* — —
Anti-TCR ab —2 1 76* 4174** 48745 9 72
Anti-TCRV b 20 — 40754 9 72** 51736 2 73
— Control Ig — 79712 — —
— Anti-HLA-ABC — 7478— —
— Anti-HLA-DR — 3677*** — —
Effusion cells were collected and cultured as described in Materials and Methods. Cytotoxic activity against autologous tumour cells and K562 tumour cells was investigated with
the treatment of effector cells and target cells with antibodies indicated. E/T¼100. Significant differences from the value without treatment, *Po0.05, **Po0.01.
12345
Fas-L
  -actin
Figure 3 Fas-L gene expression of OK/IL-2AK cells. mRNA was
extracted from effusion cells before OK-432 administration and OK/IL-
2AK cells, and Fas-L gene expression was investigated by RT–PCR analysis
using specific primers. Lane 1, molecular marker; lane 2 and 4, cells before
OK-432 administration; lanes 3 and 5, OK/IL2AK cells.
Table 5 HLA-DR expression on CEA+ or cytokeratin+ effusion cells
Surface antigens Case 1 Case 2 Case 3 Case 4
CEA+ 7
a 38 45 75
Cytokeratin+ 19 34 50 66
CD3+ 57 20 41 3
HLA-DR+ 8 87 47 82
HLA-DR+CEA+ 5 (72
b) 27 (71) 37 (81) 68 (91)
HLA-DR+cytokeratin+ 6 (30) 34 (100) 39 (78) 63 (95)
Effusion cells were collected before the treatment and stained with antibodies
indicated. Flow cytometric analysis was performed on Cytoron.
aPercentage of
surface antigen-positive cells in effusion cells analysed.
bHLA-DR+ cells in CEA+ or
cytokeratin+ cells.
Pre-OK cells
OK/IL-2AK cells
TCRV   gene usage (V   1∼ 20, C   )
5.2 9 14 15 17 1920 C  
13.2 20 C   
Figure 4 TCRVb gene analysis on OK/IL-2AK cells. Effusion cells were
collected before and after OK-432 administration from a rectal cancer
patient with malignant effusion (HLA-A11,24, B62,51, Cw4, DR9) and
TCRVb usage was analysed by RT–PCR using primer pairs specific for
TCRVb1 to 20 and Cb, followed by Southern blot hybridisation using Cb-
specific probe.
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lymphocytes induced with OK-432 plus IL-2 treatment. The
property of lymphocytes activated with OK-432 plus IL-2 has not
been fully explored, although it has been demonstrated that OK-
432-induced lymphokines facilitated the subsequent activation of
lymphocytes (Katano et al, 1991; Nanjo et al, 1991). It was
observed that the lymphocytes that infiltrated after OK-432
administration, followed by IL-2 activation in vitro (OK/IL-2AK
cells), were preferentially CD4þ T cells. This result is comparable
to an observed increase in the CD4þ population of responding
effusion cells in gastric cancer patients during the treatment
(Yamaguchi et al, 1995). The OK/IL-2AK cells produced T helper
type-1 (Th1) cytokines TNF-a and IFN-g, and that Th2 cytokines,
that is, IL-4 and IL-6, were not produced under these conditions.
Monden et al (1992) demonstrated that the intratumoral injection
of the mixture of OK-432 and fibrinogen enhanced the regression
of colorectal cancer, in which a granulomatous hypersensitive
response containing many giant cells was generated in the tumour
stroma. That feature highly resembled the delayed-type hypersen-
sitivity reaction, which is associated with Th1 responses. These
researchers also established CD4þ T-cell clones, which released a
Th1 cytokine TNF-a, in colorectal cancer patients treated by
immunotherapy using a mixture of OK-432 and fibrinogen
(Nagaoka et al, 1992). Fujimoto et al (1997) reported that OK-
432 stimulated the IL-12 production of peripheral blood mono-
nuclear cells and upregulated the Th1 phenotype. Collectively,
these findings suggest that OK-432 plus IL-2 stimulation induces
preferentially the CD4þ Th1 lymphocytes. We have reported
previously that in the murine system, there exists a tumour-
derived IL-10-associated Th1 disorder in the microenvironment of
malignant effusion, and that this disorder is overcome by the
locoregional administration of OK-432 (Hihara et al, 1999). The
Th1 disorder might occur in cases of malignant effusion from
colorectal cancers, and the locoregional upregulation of the Th1
population by OK-432 plus IL-2 may result in positive clinical
responses in the treatment of malignant effusions. The upregula-
tion of the local Th1 population by OK-432 plus IL-2, however,
failed to elicite systemic antitumour immune responses for the
distant metastases, since the systemic Th1 disorder might exist in
such terminally ill patients with malignant effusion from colorectal
cancer (Shibata et al, 2002).
Notably, it was observed that the CD4þ OK/IL-2AK cells
expressed cytotoxic activity against autologous tumour cells and
acquired Fas-L expression. Ozaki et al (1990) first described OK-
432-induced L3T4þ tumoricidal T lymphocytes in a murine
system. It has been established that certain CD4þ T cells can
express cytotoxic activity, which is associated with the Th1
phenotype and mediated with the Fas–Fas-L interaction (Hahn
et al, 1995). Stalder et al (1994) have also reported that Fas-L is an
effector molecule in CD4þ T-cell-mediated cytotoxicity, in which
the transfection of Fas antigen into target cells renders the
transfectants more susceptible to the CD4þ CTLs. Taken together,
it is strongly suggested that OK-432 plus IL-2 stimulation induces
autologous tumour-reactive CD4þ Th1 killer lymphocytes. The
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Figure 5 SSCP analysis and CDR3 sequences of TCRVb20. PCR products of TCRVb20 in Figure 4 were developed on SSCP analysis. Clonotypic bands
were sequenced and CDR3 boundaries were determined as indicated.
Pre-OK OK/IL-2AK
1234567 1234567
 -Actin
V 20-1
V 20-2
V 20-3
Figure 6 Clonotypic PCR using TCRVb20-CDR3 sequences on pre-OK
and OK/IL-2AK cells. Clonotypic PCR was performed using CDR3
sequences shown in Figure 5. Lane numbers indicated each patient
investigated. HLA haplotypes of patients were as follows: patient 1, HLA-
A11,24, B62, 51, Cw4, DR9; patient 2, HLA-A24,33, B62,44, Cw3, DR4,6;
patient 3, HLA-A24,31, B54,44, Cw1, DR4,6; patient 4, HLA-A2,10, B35,39,
Cw3,7, DR6,8; patient 5, HLA-A11,26, B67,61, Cw7, DR2,9; patient 6,
HLA-A2,31, B7,51, Cw7, DR1,12; patient 7, HLA-A24,26, B59,61, Cw1,
DR2,4.
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antigens differently from CD8þ cytotoxic T lymphocytes or NK
cells, may be a promising candidate for the effector cells of cancer
immunotherapy that targets the heterogenous clinical tumours.
It is of interest whether or not TCR and HLA molecules are
involved in the cytotoxic mechanism of the autologous tumour-
reactive CD4þ Th1 killer lymphocytes induced with OK-432 plus
IL-2. It was found that the autologous tumour-killing activity of
the OK/IL-2AK cells was significantly reduced by the treatment of
the lymphocytes with anti-TCRab antibody or by the treatment of
the autologous tumour cells with anti-HLA-DR antibody; both
results indicated that TCR and HLA class II molecules, but not
class I molecules, were involved in the cytotoxic mechanism of the
OK/IL-2AK cells. Somasundaram et al (2000) reported a CD4þ
cytotoxic T-lymphocyte clone against malignant melanoma cells,
the cytotoxicity of which was restricted with HLA class I molecules.
However, Kierstead et al (2001) demonstrated that the CD4þ
killer lymphocytes recognised antigens presented by HLA class II
molecules. Ozaki et al (1990) showed that OK-432 was presented
by Ia-positive antigen-presenting cells for OK-432-specific anti-
tumour effector T cells, which was in agreement with our
observations. In addition, flow cytometric analysis of effusion
cells using anti-CEA, -cytokeratin, and -HLA-DR antibodies
demonstrated the expression of HLA-DR molecules on CEAþ
cells and cytokeratinþ cells in the effusion, which indicated the
presence of floating cancer cells. The expression of HLA class II
molecules has been reported in many tumour cell types, including
melanoma (Ericsson et al, 2001), lung cancer (Yano et al, 2000),
and colon cancer (Bustin et al, 2001). It has also been reported that
HLA class II expression on tumour cells can be upregulated by
IFN-g (Sgagias et al, 1996; Yano et al, 2000). The microenviron-
ment of effusion may induce the expression of HLA-DR molecules
on effusion tumour cells. Together, it is suggested that the OK/IL-
2AK cells recognise the antigen(s) which is(are) presented in the
context of HLA class II molecules on a tumour cell target.
Involvement of TCR in the cytotoxic mechanism of the OK/IL-
2AK cells suggests the existence of limited TCR usage in the cells.
Finally, we investigated whether a certain TCR usage was involved
in OK-432-induced T-cell responses. The RT–PCR–Southern blot
analysis of the effusion lymphocytes showed a highly diverse usage
of the TCRVb gene in this experiment. This finding is, in general,
consistent with previous observations (Cole et al, 1997). However,
in a comparison of results before and after OK-432 treatment,
TCRVb20 usage was found to be preferentially expressed in the
OK/IL-2AK cells (Miyahara et al, 1996). OK-432 stimulation failed
to expand TCRVb20 usage in lymphocytes from healthy volunteers
(Miyahara et al, 1996). The OK/IL-2AK cells from the patient we
analysed in detail revealed an oligoclonal usage of TCRVb20.
Importantly, the autologous tumour-killing activity of the OK/IL-
2AK cells was significantly reduced by the treatment of the
lymphocytes with anti-TCRVb20 antibody as well as anti-TCRab
antibody. In addition, SSCP analysis of the TCRVb20 gene of the
OK/IL-2AK cells showed clonotypic bands. These findings strongly
indicate that the TCRVb20 was responsible for the cytotoxicity of
the OK/IL-2AK cells in that patient, and that the CDR3 of the TCR
Vb20 was limited. This may in turn suggest the existence of
antigen(s), which is(are) processed in antigen-presenting cells
during the OK-432 plus IL-2 activation, and which is(are)
recognised by the TCRVb20 of the effusion lymphocytes. This
may also suggest the existence of cross-antigenicity between
colorectal adenocarcinoma cells and OK-432. Ogawa et al (1993)
reported the presence of a common antigen between human gastric
cancer cells and OK-432. Bruno et al (1996) demonstrated the
efficiency of the immune response and showed good clinical
outcomes in bladder cancer patients treated with Bacillus
Calmette-Guerin (BCG). These researchers also indicated by the
analysis of TCR restriction patterns that bladder lymphocytes from
patients undergoing BCG treatment were oligoclonal, suggesting a
high homology between some BCG antigens and human heat-
shock proteins, which are overexpressed in human bladder cancer
cells (Bruno et al, 1996). This seems very similar to the OK-432
situation shown here. The antigen(s) recognised by the OK/IL-2AK
cells is(are) now being addressed.
If lymphocytes expressing the TCRVb20, which may recognise
the limited antigen(s), are involved in the cytotoxicity of the OK/
IL-2AK cells, it is to be investigated whether or not T cells that
express a TCR identical to the TCRVb20-CDR3 exist in effusion of
the other colorectal cancer patients. Then, the CDR3 boundaries of
the TCRVb20 gene were sequenced and used for the clonotypic
PCR analysis of locoregional cells prior to and after OK-432
administration. It was demonstrated that the positive signals of the
clonotypic PCR appeared not only in the patient in whom the
CDR3 sequences were originally cloned but also in the other
colorectal cancer patients, indicating that T cells that express a
TCR identical to the cloned TCRVb20-CDR3 really exist in effusion
of the other patients treated with our immunotherapy. Coulie et al
(2001) have emphasised the significance of the clonotypic PCR in
detecting the response of CTL precursors in the treatment of
melanoma patients, mainly because the CTL response is not always
as massive as is detectable with tetramer analysis, even in patients
with tumours that are regressing after vaccination. We are now
investigating the relevance between the clinical responses of OK-
432 immunotherapy for effusion and the TCRVb20-CDR3 expres-
sion in effusion lymphocytes. Only the accumulation of a variety of
clinical experiences can prove the significance of the clonotypic
PCR using the TCRVb20-CDR3 in the OK-432-based immunother-
apy.
In summary, locoregional administration of OK-432 alone and
OK-432 plus IL-2 was highly effective for the management of
malignant effusion from colorectal cancer. OK-432 plus IL-2
induced autologous tumour-reactive CD4þ Th1 killer lympho-
cytes, which recognised tumour antigen(s) presented with HLA
class II molecules on effusion tumour cells by means of
preferential usage of TCRVb20, and thus possibly contributing to
the clinical efficacy of this treatment. Clonotypic PCR analysis
using TCRVb20-CDR3 sequences may be informative for OK-432-
based immunotherapy in treating malignant effusion from color-
ectal cancer. This possibility is now under investigation, as is the
search for OK-432-related tumour antigen(s).
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